Fluidized Therapy (Fluidotherapy) (CPB 0450, reviewed 2026-07-09)
As last reviewed on July 9, 2026, Aetna considers fluidized therapy (fluidotherapy) medically necessary for the treatment of acute or subacute traumatic or non-traumatic musculoskeletal disorders of the extremities. Aetna considers it experimental, investigational or unproven for all other indications, including breast cancer-related lymphedema, carpal tunnel syndrome, limb edema after stroke, re-warming hypothermic subjects and rheumatoid arthritis. Fluidotherapy is a physical therapy modality subject to physical therapy guidelines and plan benefit limits, and Aetna covers only the professional charges of a physical therapist or other recognized, licensed provider for modalities that require direct, one-on-one patient contact.